San Diego-based biotech startup Fate Therapeutics, which is testing drugs that help spur the body’s own adult stem cells to action to stimulate healing and block cancer growth, said it has acquired exclusive rights to a stem cell technology from Children’s Hospital Boston and Massachusetts General Hospital.
The intellectual property covers compositions and methods for supporting blood-producing stem cells, known as hematopoietic cells.
Leonard Zon, director of the stem cell program at Children’s and a scientific founder of Fate, developed the stem cell technology.
Financial terms of the deal were not released.
, Heather Chambers